Ocugen (OCGN)

Last close As at 13/08/2025

USD1.03

0.00 (0.00%)

Market capitalisation

USD302m

Ocugen is a clinical-stage biotechnology company developing novel gene therapies to treat blinding retinal diseases, and its subsidiary is advancing cell therapies for orthopaedic indications.

Latest Insights

Healthcare | Non client QV

Ocugen — Novel cell therapies for retinal diseases

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Shankar Musunuri

    CEO

  • Ramesh Ramachandran

    Chief Accounting Officer

Thematics

thematic

Healthcare

Healthcare-focused trusts: A sector on the mend

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free